Treace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. Patent
15 9월 2023 - 5:05AM
Treace Medical Concepts, Inc. (“Treace” or the “Company”)
(NasdaqGS: TMCI), a medical technology company driving a
fundamental shift in the surgical treatment of hallux valgus
(commonly known as bunions) through its Lapiplasty® 3D Bunion
Correction® Procedure, is pleased to announce the United States
Patent and Trademark Office’s (USPTO) forthcoming issuance of U.S.
Patent No. 11,771,467, to publish on October 3, 2023 (the ‘467
Patent).
“Our 50th U.S. Patent grant demonstrates our
commitment to rapid and meaningful innovation that continues to set
the standard in our field,” said John T. Treace, CEO, Founder and
Board Member of Treace. “Our pioneering work in the bunion
correction space dates back over nine years now. An increasing
number of physicians and their patients rely on our technology
advancements, which we will continue to rapidly develop and protect
as part of the Company’s strategy.”
The ‘467 Patent has a July 15, 2014 priority
date and covers foundational steps for improved correction of
bunion deformities. Treace’s innovation continues to advance the
standard of care in bunion correction and is recognized by the
USPTO, along with patent offices around the world, as novel. The
company now has 50 U.S. patents, 12 patents worldwide, and 76
pending patent applications.
Internet Posting of
Information
Treace routinely posts information that may be
important to investors in the “Investor Relations” section of its
website at www.treace.com. The Company encourages investors and
potential investors to consult the Treace website regularly for
important information about Treace.
About Treace Medical
Concepts
Treace Medical Concepts, Inc. is a medical
technology company with the goal of advancing the standard of care
for the surgical management of bunion and related midfoot
deformities. Bunions are complex 3-dimensional deformities that
originate from an unstable joint in the middle of the foot and
affect approximately 65 million Americans, of which Treace
estimates 1.1 million are annual surgical candidates. Treace has
pioneered and patented the Lapiplasty® 3D Bunion Correction® System
– a combination of instruments, implants, and surgical methods
designed to surgically correct all 3 planes of the bunion deformity
and secure the unstable joint, addressing the root cause of the
bunion and helping patients get back to their active lifestyles.
Treace expanded its offering with the Adductoplasty® Midfoot
Correction System, designed for reproducible surgical correction of
the midfoot to provide further support to hallux valgus patients.
For more information, please visit www.treace.com.
To learn more about Treace, connect with us on
LinkedIn, Twitter, Facebook and Instagram.
Contacts:
Treace Medical Concepts,
Inc.Julie Dewey, IRCChief Communications & Investor
Relations Officerjddewey@treace.com | 209-613-6945
Treace Medical Concepts (NASDAQ:TMCI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Treace Medical Concepts (NASDAQ:TMCI)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024